KalVista Pharmaceuticals (NASDAQ:KALV) Rating Reiterated by Needham & Company LLC

KalVista Pharmaceuticals (NASDAQ:KALV)‘s stock had its “buy” rating reaffirmed by equities research analysts at Needham & Company LLC in a research report issued on Tuesday, Benzinga reports. They currently have a $35.00 price target on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price objective would suggest a potential upside of 207.83% from the company’s previous close.

Separately, HC Wainwright reduced their price objective on KalVista Pharmaceuticals from $24.00 to $20.00 and set a “buy” rating on the stock in a research note on Friday, May 3rd.

KalVista Pharmaceuticals Trading Down 3.8 %

NASDAQ:KALV opened at $11.37 on Tuesday. The firm’s fifty day simple moving average is $11.71 and its 200 day simple moving average is $12.24. KalVista Pharmaceuticals has a twelve month low of $7.21 and a twelve month high of $16.88. The firm has a market capitalization of $479.70 million, a price-to-earnings ratio of -3.61 and a beta of 0.90.

Insider Transactions at KalVista Pharmaceuticals

In related news, CEO Benjamin L. Palleiko sold 21,959 shares of the firm’s stock in a transaction on Monday, May 20th. The shares were sold at an average price of $11.76, for a total transaction of $258,237.84. Following the completion of the sale, the chief executive officer now directly owns 216,387 shares of the company’s stock, valued at approximately $2,544,711.12. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 7,465 shares of the company’s stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $11.53, for a total value of $86,071.45. Following the transaction, the chief executive officer now directly owns 224,547 shares of the company’s stock, valued at approximately $2,589,026.91. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Benjamin L. Palleiko sold 21,959 shares of the stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $11.76, for a total value of $258,237.84. Following the transaction, the chief executive officer now owns 216,387 shares of the company’s stock, valued at $2,544,711.12. The disclosure for this sale can be found here. Over the last three months, insiders have sold 37,512 shares of company stock valued at $439,424. Corporate insiders own 12.30% of the company’s stock.

Institutional Trading of KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC lifted its holdings in KalVista Pharmaceuticals by 28.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,482 shares of the specialty pharmaceutical company’s stock worth $43,000 after buying an additional 768 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in KalVista Pharmaceuticals in the fourth quarter worth $49,000. AJOVista LLC acquired a new position in KalVista Pharmaceuticals in the fourth quarter worth $60,000. EntryPoint Capital LLC bought a new stake in KalVista Pharmaceuticals during the first quarter valued at $92,000. Finally, New York State Common Retirement Fund lifted its position in shares of KalVista Pharmaceuticals by 1,860.4% in the 3rd quarter. New York State Common Retirement Fund now owns 9,959 shares of the specialty pharmaceutical company’s stock worth $96,000 after buying an additional 9,451 shares during the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.